- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04422756
Prospective Evaluation of Confirmatory Testing For Primary Aldosteronism
May 9, 2023 updated by: University of Calgary
This study is to evaluate the performance characteristics of the seated saline infusion test and the ultra low-dose ACTH stimulation test for the diagnosis of primary aldosteronism.
Study Overview
Status
Recruiting
Conditions
Detailed Description
This is a prospective study (with a target recruitment of 200 participants) designed to evaluate the performance characteristics of the seated saline infusion test and the ultra low-dose ACTH stimulation test for the diagnosis of primary aldosteronism, using disease-specific treatment response as a reference gold standard.
Subjects consenting to study participation will undergo a standardized seated saline infusion test, followed by an ultra low-dose ACTH stimulation test.
All participants also receive adrenal vein sampling.
Individuals who have unilateral disease and desire surgery will receive adrenalectomy (as part of routine care) and the remaining subjects will receive medical treatment with a mineralocorticoid receptor antagonist.
Response to targeted treatment will be considered the reference gold standard for the establishing the diagnosis of primary aldosteronism.
Study Type
Observational
Enrollment (Anticipated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Alexander Leung, MD
- Phone Number: (403) 955-8358
- Email: aacleung@ucalgary.ca
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada
- Recruiting
- University of Calgary
-
Contact:
- Alexander Leung, MD
- Phone Number: (403) 955-8358
- Email: aacleung@ucalgary.ca
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Hypertension individuals suspected of having primary aldosteronism.
Description
Inclusion Criteria:
- Individuals with hypertension
- Individuals with an elevated screening adrenal renin ration (ARR)
- Individuals with high probability features of primary aldosteronism (e.g., resistant hypertension, spontaneous or diuretic-induced hypokalemia, and/or an adrenal nodule) with clinical indications for adrenal vein sampling and surgery (if appropriate).
Exclusion Criteria:
- Individuals with chronic kidney disease (estimated glomerular filtration rate <40 mL/min/1.73m2),
- Individuals with a history of heart failure, chronic edema, uncontrolled severe hypertension (systolic blood pressure >180 and/or diastolic blood pressure >110 mmHg), untreated hypokalemia, cortisol-secreting adrenal adenoma, and/or pheochromocytoma
- Individual who previously received confirmatory testing.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnostic accuracy of confirmatory testing (seated saline infusion test and the ultra low-dose ACTH stimulation test)
Time Frame: The total study timeline will occur over 66 months.
|
Measures of diagnostic accuracy, as summarized by receiver operating characteristic curve analyses.
|
The total study timeline will occur over 66 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The optimal cutoff value for confirmatory testing using clinically-important thresholds
Time Frame: The total study timeline will occur over 66 months.
|
Plasma aldosterone
|
The total study timeline will occur over 66 months.
|
The optimal cutoff value for confirmatory testing using clinically-important thresholds
Time Frame: The total study timeline will occur over 66 months.
|
Aldosterone-to-renin ratio
|
The total study timeline will occur over 66 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Alexander Leung, Asst. Prof, University of Calgary
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2.
- Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallee M, Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Drouin D, Lavoie KL, Hamet P, Fodor G, Gregoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Harris KC, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM; CHEP Guidelines Task Force. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Can J Cardiol. 2016 May;32(5):569-88. doi: 10.1016/j.cjca.2016.02.066. Epub 2016 Mar 10.
- Mulatero P, Milan A, Fallo F, Regolisti G, Pizzolo F, Fardella C, Mosso L, Marafetti L, Veglio F, Maccario M. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab. 2006 Jul;91(7):2618-23. doi: 10.1210/jc.2006-0078. Epub 2006 May 2.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 15, 2017
Primary Completion (Anticipated)
December 31, 2023
Study Completion (Anticipated)
December 31, 2023
Study Registration Dates
First Submitted
May 27, 2020
First Submitted That Met QC Criteria
June 5, 2020
First Posted (Actual)
June 9, 2020
Study Record Updates
Last Update Posted (Actual)
May 10, 2023
Last Update Submitted That Met QC Criteria
May 9, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REB16-2322
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Aldosteronism
-
Radboud University Medical CenterCompletedPrimary Aldosteronism | Primary HyperaldosteronismNetherlands
-
Shanghai Jiao Tong University School of MedicineNot yet recruitingPrimary AldosteronismChina
-
University of CalgaryNot yet recruiting
-
Queen Mary University of LondonRecruiting
-
First Affiliated Hospital of Chengdu Medical CollegeNot yet recruitingPrimary AldosteronismChina
-
University College London HospitalsCompletedPrimary Aldosteronism
-
Shanghai Zhongshan HospitalCompleted
-
Qifu LiWest China Hospital; Tongji Hospital; Second Affiliated Hospital, School of Medicine... and other collaboratorsRecruitingPrimary AldosteronismChina
-
Xiao ChenRecruitingPrimary AldosteronismChina
-
Liverpool University Hospitals NHS Foundation TrustRecruiting
Clinical Trials on Seated intravenous saline infusion test
-
Chongqing Medical UniversityCompletedPrimary AldosteronismChina
-
Chongqing Medical UniversityCompletedPrimary AldosteronismChina
-
University Hospital, Gentofte, CopenhagenRecruitingPostPrandial HypotensionDenmark
-
University at BuffaloAmerican Diabetes AssociationCompleted
-
University Hospital, LinkoepingRegion Örebro County; Blekingesjukhuset, KarlskronaCompletedMyocardial Infarction | Myocardial Ischemia | Coronary Artery Disease | Coronary Artery BypassSweden
-
National Hepatology & Tropical Medicine Research...CompletedLiver Function Post BCAA InfusionEgypt
-
Shaoxing Second HospitalUnknown
-
Catholic University of the Sacred HeartSteno Diabetes Center CopenhagenCompletedType 2 Diabetes MellitusItaly
-
Bispebjerg HospitalPsychiatric Centre RigshospitaletCompletedCognitive Change | Type2 Diabetes | KetonemiaDenmark
-
T.C. ORDU ÜNİVERSİTESİActive, not recruitingAthletic Injuries | Sports Physical TherapyTurkey